LQDA Liquidia Corp
Data as of close
Healthcare · Pharmaceutical Preparations
Liquidia Corp (LQDA) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $4.2 billion. Shares last traded at $47.39, 49.4% below their 52-week high. Over the past year the stock is up 88.2%. LQDA trades at a price-to-earnings ratio of 30.60, above the Pharmaceutical Preparations median of 15.85. Net profit margin is 30.7%, above the peer median of -7.0%. Revenue grew 1031.2% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.74 | 2026-08-12 |
| Q1 2026 | $0.52 | 2026-05-11 |
| Q4 2025 (derived) | $0.18 | 2026-03-05 |
| FY 2025 | -$0.80 | 2026-03-05 |
| Q3 2025 | -$0.04 | 2025-11-03 |
| Q2 2025 | -$0.49 | 2025-08-12 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
LQDA vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.37 | 15.43 | 31.9% | +0.62% |
| JNJ | Johnson & Johnson | $665.2B | 41.33 | 6.70 | 16.2% | +3.82% |
| ONC | Beone Medicines Ltd. | $558.0B | 850.93 | 91.04 | 10.7% | +6.36% |
| ABBV | AbbVie | $521.3B | 50.40 | 7.90 | 15.7% | +3.16% |
| MRK | Merck | $370.7B | 151.12 | 5.50 | 3.6% | +3.93% |
| ABT | Abbott Laboratories | $200.2B | 42.58 | 4.15 | 9.7% | +5.61% |
| PFE | Pfizer | $175.5B | 43.52 | 2.76 | 6.3% | +2.70% |
| VRTX | Vertex Pharmaceuticals | $139.2B | 35.01 | 10.75 | 30.7% | +3.37% |
| BMY | Bristol Myers Squibb | $131.2B | 14.20 | 2.62 | 18.5% | +4.04% |
| REGN | Regeneron Pharmaceuticals | $96.3B | 19.99 | 5.70 | 28.5% | -4.41% |
| TEVA | Teva Pharmaceutical Industries Ltd | $48.8B | 96.39 | 2.83 | 2.9% | -0.24% |
| ZTS | Zoetis | $36.8B | 14.08 | 3.87 | 27.5% | +7.40% |
| RPRX | Royalty Pharma Plc | $30.1B | 44.80 | 11.50 | 25.7% | +1.82% |
| ROIV | Roivant Sciences Ltd. | $27.6B | — | 3665.32 | — | +5.99% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.